The U.S. government has secured a 71 percent discount off the list price for Novo Nordisk's blockbuster drugs Ozempic and Wegovy for patients covered by Medicare, the federal health insurance program for seniors.
The newly announced prices are the result of a law passed during the Biden era and will take effect in 2027.
Other top-selling medications, such as Pfizer's breast cancer drug Ibrance, will see a 50 percent price reduction compared to the 2024 list price, according to a statement from the Centers for Medicare and Medicaid Services.